U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07532486) titled 'A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis' on April 08.
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese participants with moderate to severe plaque psoriasis.
Study Start Date: July 10, 2024
Study Type: INTERVENTIONAL
Condition:
Psoriasis
Intervention:
DRUG: Guselkumab
Participants will receive 2 injections of active guselkumab (as 200 mg, SC) a...